Find and Pitch Jounalists, Get Your Story Covered

Tags: cabozantinib atezolizumab prostate cancer docetaxel castrate-resistant prostate cancer

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Amivantamab plus lazertinib shows survival benefit in lung cancer - 22 days ago Amgen’s trial brings new hope for IgG4-RD patients - 11 months ago
2	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology - 22 days ago
3	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	New Bispecific Shrinks NRG1 Fusion-Positive Lung, Pancreatic Tumors - 2 months ago FDA Approves Zanidatamab for Biliary Tract Cancer - 5 months ago Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain Mets - 7 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 7 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 8 months ago Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC - about 1 year ago Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - about 1 year ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - about 1 year ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - over 1 year ago Axatilimab Shows Efficacy in Recurrent/Refractory GVHD - over 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - over 1 year ago
4	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Tislelizumab in Combination With Chemotherapy for Gastric, Gastrosophageal Junction Adenocarcinoma - 4 months ago Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 7 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 8 months ago FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 10 months ago FDA Accepts sBLA for Bimekizumab-bkzx in Hidradenitis Suppurativa Treatment - about 1 year ago Study: Lebrikizumab Demonstrates Improvements in Atopic Dermatitis for Patients of Color - about 1 year ago FDA Approves Tocilizumab-aazg as Biosimilar to Actemra for Multiple Indications - about 1 year ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - about 1 year ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - about 1 year ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - about 1 year ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - over 1 year ago
5	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Testing Elacestrant With Other Targeted Drugs for Metastatic Breast Cancer - 4 months ago Inebilizumab for Myasthenia Gravis Reduces Steroid Burden - 5 months ago Cabozantinib Plus Atezolizumab Improves PFS in Metastatic CRPC - about 1 year ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - over 1 year ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - over 1 year ago Dato-DXd More Effective, Tolerable Than Chemo for Metastatic Breast Cancer - over 1 year ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - over 1 year ago T-DXd Could Be 'Practice-Changing' in HER2-Expressing Gynecologic Cancers - over 1 year ago New Data on Bimekizumab in Psoriatic Arthritis - over 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - over 1 year ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - over 1 year ago IL-13 Blocker for Eczema Maintains Efficacy at Less-Frequent Dosing - over 1 year ago
6	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	SABCS 2024: Combination of Elacestrant and Abemaciclib Shows Promising Progression-Free Survival in ER+/HER2- Advanced Breast Cancer - 4 months ago Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - 5 months ago CHMP Recommends Lazertinib With Amivantamab to Treat EGFR-Mutated Advanced NSCLC - 5 months ago
7	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 6 months ago
8	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Lebrikizumab Wins FDA Approval for Eczema - 7 months ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - over 1 year ago Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years - over 1 year ago
9	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	MHRA approves Astellas’ Vyloy combination for gastric cancer - 8 months ago
10	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors - about 1 year ago FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - about 1 year ago

Journalists covering atezolizumab